Argent Biopharma Ltd

H5O0

Company Profile

  • Business description

    Argent Biopharma Ltd is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialization of nano-engineered therapeutics targeting neurological and immunemediated disorders. Its assets, CannEpil and CimetrA, are for drug-resistant epilepsy and inflammatory conditions, respectively. The company leverages proprietary nano-delivery technologies designed to optimize bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. The company operates in a single segment. Geographically, it operates in Malta, Slovenia, UK, and Australia, with the majority of revenue deriving from Slovenia.

  • Contact

    295 Rokeby Road
    Suite 1
    SubiacoWA6008
    AUS

    T: +61 865552950

    E: [email protected]

    https://www.argentbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    Employees

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,147.33949.73-1.93%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,617.731,261.47-5.28%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,910.39265.44-3.70%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers